Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib with 7+3 induction chemotherapy in high-risk AML
NCT02560025Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2015
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in acute myeloid leukemia (AML), sponsored by Massachusetts General Hospital. Started Dec 2015; status: completed.
02
Drugs
alisertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02560025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560025.